Pfizer to acquire Hospira for $16B

Laura Pedulli | | Health Exec | Management

In a deal that will transform the pharmaceutical industry, Pfizer announced that it will buy rival Hospira for $16 billion, reports Wall Street Journal.

The purchase is expected to make Pfizer a leading player in the emerging market for lower-priced versions of costly biotech drugs, according to the article.

Read more below:

Pfizer to Buy Hospira for $16 Billion

Laura Pedulli

Related Content

Hospital and police department feud over baggie of drugs in patient’s rectum
Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits

Around the web

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year.